These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37537462)

  • 1. [SGLT2-inhibitors (gliflozins) - multipurpose medications and the statins of the 21st century?].
    Zeeh J
    MMW Fortschr Med; 2023 Aug; 165(14):46-48. PubMed ID: 37537462
    [No Abstract]   [Full Text] [Related]  

  • 2. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.
    Santulli G; Varzideh F; Forzano I; Wilson S; Salemme L; de Donato A; Lombardi A; Rainone A; Nunziata L; Jankauskas SS; Tesorio T; Guerra G; Kansakar U; Mone P
    Hypertension; 2023 Sep; 80(9):1800-1809. PubMed ID: 37403685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Empagliflozin in the elderly].
    Berrut G; Boureau AS; Trochu JN; Genet B; de Decker L; Hanon O
    Geriatr Psychol Neuropsychiatr Vieil; 2021 Jun; 19(2):137-147. PubMed ID: 34165436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibitors: the statins of the 21st century.
    Braunwald E
    Eur Heart J; 2022 Mar; 43(11):1029-1030. PubMed ID: 34741610
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of sodium-glucose cotransporter 2 inhibitors beyond the cardio-renal-metabolic spectrum: will gliflozins have a different fate than statins?
    Koufakis T; Tsimihodimos V; Metallidis S; Kotsa K; Doumas M
    Expert Opin Pharmacother; 2023; 24(16):1753-1756. PubMed ID: 37594789
    [No Abstract]   [Full Text] [Related]  

  • 6. [Role of SGLT2 inhibitors (gliflozins) in heart failure].
    Scheen AJ; Ancion A; Lancellotti P
    Rev Med Suisse; 2022 Aug; 18(792):1546-1550. PubMed ID: 36004654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [SGLT2 inhibitors - a new pillar for the treatment of heart failure].
    Tavačová D; Václavík J
    Vnitr Lek; 2021; 67(8):475-478. PubMed ID: 35459367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin for heart failure: is it a class effect?
    Raj GM; Wyawahare M
    Future Cardiol; 2021 Mar; 17(2):355-361. PubMed ID: 32755319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes.
    Siamashvili M; Davis SN
    Expert Opin Pharmacother; 2021 Nov; 22(16):2181-2198. PubMed ID: 34388350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review.
    Hoehlschen J; Hofreither D; Tomin T; Birner-Gruenberger R
    Cardiovasc Diabetol; 2023 Apr; 22(1):101. PubMed ID: 37120524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT-2 Inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus.
    Kumar K; Behl T; Kumar A; Arora S
    Curr Mol Pharmacol; 2021 Oct; 14(4):487-497. PubMed ID: 33045972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.
    Chen S; Wang Q; Christodoulou A; Mylonas N; Bakker D; Nederlof R; Hollmann MW; Weber NC; Coronel R; Wakker V; Christoffels VM; Andreadou I; Zuurbier CJ
    Circulation; 2023 Jan; 147(3):276-279. PubMed ID: 36649392
    [No Abstract]   [Full Text] [Related]  

  • 18. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
    Rizos EC; Elisaf MS
    Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.